Chinese General Practice ›› 2023, Vol. 26 ›› Issue (11): 1340-1347.DOI: 10.12114/j.issn.1007-9572.2022.0738
Special Issue: 中医最新文章合集
• Original Research • Previous Articles Next Articles
Received:
2022-07-20
Revised:
2022-12-10
Published:
2023-04-15
Online:
2023-01-03
Contact:
ZHU Wenzeng
About author:
通讯作者:
朱文增
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0738
项目 | 文献数(篇) | 占比(%) | 项目 | 文献数(篇) | 占比(%) | ||
---|---|---|---|---|---|---|---|
发表年份(年) | 治疗周期(周) | ||||||
[1992,1996] | 4 | 2.15 | [1,4) | 12 | 6.45 | ||
[1997,2001] | 4 | 2.15 | [4,8) | 36 | 19.35 | ||
[2002,2006] | 22 | 11.83 | [8,12) | 30 | 16.13 | ||
[2007,2011] | 31 | 16.67 | [12,16) | 47 | 25.27 | ||
[2012,2016] | 58 | 31.18 | [16,24) | 2 | 1.08 | ||
[2017,2021] | 67 | 36.02 | [24,32) | 25 | 13.44 | ||
随访次数(次) | [32,40) | 4 | 2.15 | ||||
2 | 1 | 0.54 | [40,48) | 0 | 0.00 | ||
3 | 155 | 83.33 | [48,52) | 3 | 1.61 | ||
4 | 16 | 8.60 | [52,60) | 2 | 1.08 | ||
5 | 3 | 1.61 | [60,208] | 7 | 3.76 | ||
6 | 2 | 1.08 | 未报告 | 18 | 9.68 | ||
7 | 1 | 0.54 | 单篇RCT结局指标数(个) | ||||
未报告 | 8 | 4.30 | [ | 110 | 59.14 | ||
盲法 | [ | 49 | 26.34 | ||||
受试者与试验人员设盲 | 12 | 6.45 | [ | 20 | 10.75 | ||
未报告 | 174 | 93.55 | [ | 7 | 3.76 |
Table 1 Basic characteristics of randomized controlled trials of myasthenia gravis treated with traditional Chinese medicine
项目 | 文献数(篇) | 占比(%) | 项目 | 文献数(篇) | 占比(%) | ||
---|---|---|---|---|---|---|---|
发表年份(年) | 治疗周期(周) | ||||||
[1992,1996] | 4 | 2.15 | [1,4) | 12 | 6.45 | ||
[1997,2001] | 4 | 2.15 | [4,8) | 36 | 19.35 | ||
[2002,2006] | 22 | 11.83 | [8,12) | 30 | 16.13 | ||
[2007,2011] | 31 | 16.67 | [12,16) | 47 | 25.27 | ||
[2012,2016] | 58 | 31.18 | [16,24) | 2 | 1.08 | ||
[2017,2021] | 67 | 36.02 | [24,32) | 25 | 13.44 | ||
随访次数(次) | [32,40) | 4 | 2.15 | ||||
2 | 1 | 0.54 | [40,48) | 0 | 0.00 | ||
3 | 155 | 83.33 | [48,52) | 3 | 1.61 | ||
4 | 16 | 8.60 | [52,60) | 2 | 1.08 | ||
5 | 3 | 1.61 | [60,208] | 7 | 3.76 | ||
6 | 2 | 1.08 | 未报告 | 18 | 9.68 | ||
7 | 1 | 0.54 | 单篇RCT结局指标数(个) | ||||
未报告 | 8 | 4.30 | [ | 110 | 59.14 | ||
盲法 | [ | 49 | 26.34 | ||||
受试者与试验人员设盲 | 12 | 6.45 | [ | 20 | 10.75 | ||
未报告 | 174 | 93.55 | [ | 7 | 3.76 |
结局指标分类 | 结局指标名称 | 文献数(篇) | 占比(%) |
---|---|---|---|
1.MG严重程度量表 | 重症肌无力绝对和相对评分法(MG-ARS) | 104 | 55.91 |
重症肌无力定量评分(QMG) | 23 | 12.37 | |
重症肌无力复合量表(MGC) | 3 | 1.61 | |
肌无力疲劳程度评分(MWSS) | 1 | 0.54 | |
徒手肌力量表(MMT) | 1 | 0.54 | |
急性生理与慢性健康评分(APACHEⅡ评分) | 1 | 0.54 | |
2.MG生活质量相关量表 | Busch生活质量量表 | 7 | 3.76 |
重症肌无力生活能力量表(MG-ADL) | 5 | 2.69 | |
SF-36生活质量量表 | 3 | 1.61 | |
重症肌无力生活质量量表(MG-QOL) | 3 | 1.61 | |
重症肌无力报告结局量表(MG-PRO) | 2 | 1.08 | |
3.中医证候积分 | — | 70 | 37.63 |
4.安全性指标 | — | 66 | 35.48 |
5.血生化指标 | |||
神经免疫学抗体 | 乙酰胆碱受体抗体(AChR-Ab) | 28 | 15.05 |
肌联蛋白抗体(Titin-Ab) | 1 | 0.54 | |
骨骼肌酪氨酸激酶抗体(MuSK-Ab) | 1 | 0.54 | |
T淋巴细胞亚群 | CD4+ | 16 | 8.60 |
CD4+/CD8+ | 16 | 8.60 | |
CD8+ | 14 | 7.53 | |
CD3+ | 11 | 5.91 | |
T调节细胞(Treg) | 6 | 3.23 | |
T辅助细胞17(Th17) | 4 | 2.15 | |
T淋巴细胞转化率 | 2 | 1.08 | |
T辅助细胞1(Th1) | 1 | 0.54 | |
T辅助细胞2(Th2) | 1 | 0.54 | |
细胞毒性T淋巴细胞/抑制T淋巴细胞(Tc/Ts) | 1 | 0.54 | |
CD19+ | 1 | 0.54 | |
细胞因子 | 白介素6(IL-6) | 8 | 4.30 |
干扰素γ(INF-γ) | 7 | 3.76 | |
肿瘤坏死因子α(TNF-α) | 6 | 3.23 | |
白介素4(IL-4) | 5 | 2.69 | |
可溶性白介素-2受体(sIL-2R) | 4 | 2.15 | |
白介素17(IL-17) | 3 | 1.61 | |
白介素18(IL-18) | 3 | 1.61 | |
B细胞刺激因子受体(BAFF-R) | 2 | 1.08 | |
白介素8(IL-8) | 1 | 0.54 | |
转化生长因子β(TGF-β) | 1 | 0.54 | |
可溶性白介素6受体(sIL-6R) | 1 | 0.54 | |
白介素21(IL-21) | 1 | 0.54 | |
白介素1β(IL-1β) | 1 | 0.54 | |
B细胞刺激因子(BAFF) | 1 | 0.54 | |
补体与免疫蛋白 | IgM | 14 | 7.53 |
IgA | 14 | 7.53 | |
补体C3 | 12 | 6.45 | |
IgG | 12 | 6.45 | |
补体C4 | 9 | 4.84 | |
IgG1 | 2 | 1.08 | |
IgE | 2 | 1.08 | |
IgG3 | 2 | 1.08 | |
IgG2 | 1 | 0.54 | |
IgG4 | 1 | 0.54 | |
其他 | 自然杀伤细胞(NK细胞) | 2 | 1.08 |
程序性死亡蛋白1及其配体(PD-1/PD-L1) | 1 | 0.54 | |
白细胞计数 | 1 | 0.54 | |
血小板计数 | 1 | 0.54 | |
血液pH值 | 1 | 0.54 | |
氧合指数 | 1 | 0.54 | |
低密度脂蛋白受体相关蛋白4(LRP4) | 1 | 0.54 | |
6.肌力变化 | 肌力评级 | 2 | 1.08 |
握力值测量 | 1 | 0.54 | |
7.其他指标 | 有效率 | 175 | 94.09 |
复发率 | 11 | 5.91 | |
西药减停量 | 7 | 3.76 | |
重复神经电刺激衰减率(RNS) | 7 | 3.76 | |
颈总动脉、颈内动脉、颈外动脉血流速度 | 2 | 1.08 | |
呼吸机脱机率 | 1 | 0.54 | |
浅快呼吸指数(RSBI) | 1 | 0.54 | |
6 min步行试验(6MWT) | 1 | 0.54 | |
肌无力危象发生率 | 1 | 0.54 | |
机械通气时长 | 1 | 0.54 | |
并发症 | 1 | 0.54 |
Table 2 Classification and frequency of outcomes used in randomized controlled trials of myasthenia gravis treated with traditional Chinese medicine
结局指标分类 | 结局指标名称 | 文献数(篇) | 占比(%) |
---|---|---|---|
1.MG严重程度量表 | 重症肌无力绝对和相对评分法(MG-ARS) | 104 | 55.91 |
重症肌无力定量评分(QMG) | 23 | 12.37 | |
重症肌无力复合量表(MGC) | 3 | 1.61 | |
肌无力疲劳程度评分(MWSS) | 1 | 0.54 | |
徒手肌力量表(MMT) | 1 | 0.54 | |
急性生理与慢性健康评分(APACHEⅡ评分) | 1 | 0.54 | |
2.MG生活质量相关量表 | Busch生活质量量表 | 7 | 3.76 |
重症肌无力生活能力量表(MG-ADL) | 5 | 2.69 | |
SF-36生活质量量表 | 3 | 1.61 | |
重症肌无力生活质量量表(MG-QOL) | 3 | 1.61 | |
重症肌无力报告结局量表(MG-PRO) | 2 | 1.08 | |
3.中医证候积分 | — | 70 | 37.63 |
4.安全性指标 | — | 66 | 35.48 |
5.血生化指标 | |||
神经免疫学抗体 | 乙酰胆碱受体抗体(AChR-Ab) | 28 | 15.05 |
肌联蛋白抗体(Titin-Ab) | 1 | 0.54 | |
骨骼肌酪氨酸激酶抗体(MuSK-Ab) | 1 | 0.54 | |
T淋巴细胞亚群 | CD4+ | 16 | 8.60 |
CD4+/CD8+ | 16 | 8.60 | |
CD8+ | 14 | 7.53 | |
CD3+ | 11 | 5.91 | |
T调节细胞(Treg) | 6 | 3.23 | |
T辅助细胞17(Th17) | 4 | 2.15 | |
T淋巴细胞转化率 | 2 | 1.08 | |
T辅助细胞1(Th1) | 1 | 0.54 | |
T辅助细胞2(Th2) | 1 | 0.54 | |
细胞毒性T淋巴细胞/抑制T淋巴细胞(Tc/Ts) | 1 | 0.54 | |
CD19+ | 1 | 0.54 | |
细胞因子 | 白介素6(IL-6) | 8 | 4.30 |
干扰素γ(INF-γ) | 7 | 3.76 | |
肿瘤坏死因子α(TNF-α) | 6 | 3.23 | |
白介素4(IL-4) | 5 | 2.69 | |
可溶性白介素-2受体(sIL-2R) | 4 | 2.15 | |
白介素17(IL-17) | 3 | 1.61 | |
白介素18(IL-18) | 3 | 1.61 | |
B细胞刺激因子受体(BAFF-R) | 2 | 1.08 | |
白介素8(IL-8) | 1 | 0.54 | |
转化生长因子β(TGF-β) | 1 | 0.54 | |
可溶性白介素6受体(sIL-6R) | 1 | 0.54 | |
白介素21(IL-21) | 1 | 0.54 | |
白介素1β(IL-1β) | 1 | 0.54 | |
B细胞刺激因子(BAFF) | 1 | 0.54 | |
补体与免疫蛋白 | IgM | 14 | 7.53 |
IgA | 14 | 7.53 | |
补体C3 | 12 | 6.45 | |
IgG | 12 | 6.45 | |
补体C4 | 9 | 4.84 | |
IgG1 | 2 | 1.08 | |
IgE | 2 | 1.08 | |
IgG3 | 2 | 1.08 | |
IgG2 | 1 | 0.54 | |
IgG4 | 1 | 0.54 | |
其他 | 自然杀伤细胞(NK细胞) | 2 | 1.08 |
程序性死亡蛋白1及其配体(PD-1/PD-L1) | 1 | 0.54 | |
白细胞计数 | 1 | 0.54 | |
血小板计数 | 1 | 0.54 | |
血液pH值 | 1 | 0.54 | |
氧合指数 | 1 | 0.54 | |
低密度脂蛋白受体相关蛋白4(LRP4) | 1 | 0.54 | |
6.肌力变化 | 肌力评级 | 2 | 1.08 |
握力值测量 | 1 | 0.54 | |
7.其他指标 | 有效率 | 175 | 94.09 |
复发率 | 11 | 5.91 | |
西药减停量 | 7 | 3.76 | |
重复神经电刺激衰减率(RNS) | 7 | 3.76 | |
颈总动脉、颈内动脉、颈外动脉血流速度 | 2 | 1.08 | |
呼吸机脱机率 | 1 | 0.54 | |
浅快呼吸指数(RSBI) | 1 | 0.54 | |
6 min步行试验(6MWT) | 1 | 0.54 | |
肌无力危象发生率 | 1 | 0.54 | |
机械通气时长 | 1 | 0.54 | |
并发症 | 1 | 0.54 |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
冯天笑,李康健,于大伟,等. 中医手法治疗神经根型颈椎病随机对照试验结局指标的现状研究[J]. 中国全科医学,2022,25(20):2525-2533,2540.
|
[8] |
张明妍,张俊华,张伯礼,等. 中医药临床试验核心指标集研制技术规范[J]. 中华中医药杂志,2021,36(2):924-928.
|
[9] |
刘炳林. 药物临床试验中疗效指标的选择[J]. 中国新药杂志,2017,26(18):2113-2120.
|
[10] | |
[11] |
严玉英. 习练八段锦对重症肌无力ⅡA型患者生存质量的影响[D]. 广州:广州中医药大学,2020.
|
[12] |
黎健鹏. 背俞穴埋线治疗脾胃虚损型Ⅰ、Ⅱ型重症肌无力疗效观察[D]. 广州:广州中医药大学,2020.
|
[13] |
徐瑶,黄玲,陈红,等. 重症肌无力绝对与相对评分法的改良与评价研究[J]. 中华神经医学杂志,2018,17(7):710-715. DOI:10.3760/cma.j.issn.1671-8925.2018.07.011.
|
[14] |
|
[15] |
中国医师协会中西医结合医师分会,中国中西医结合学会循证医学专业委员会. 中医药与中西医结合临床研究方法指南[J]. 中国中西医结合杂志,2015,35(8):901-932.
|
[16] |
|
[17] |
李守凤,刘晓琳,张译文,等. 透皮贴剂Ⅰ期临床试验设计考量要点[J]. 中国临床药理学杂志,2022,38(13):1535-1538,1543. DOI:10.13699/j.cnki.1001-6821.2022.13.022.
|
[18] | |
[19] |
杨小英,张雅静,冯硕,等. 中药随机对照试验作为证据利用的影响因素及改进策略[J]. 中国中西医结合杂志,2018,38(8):1002-1005.
|
[20] |
|
[21] |
|
[22] |
|
[23] |
于长禾,孙亚男,何丽云,等. 建立中医药临床研究核心结局指标集[J]. 中华中医药杂志,2016,31(7):2526-2529.
|
[24] |
邱瑞瑾,孙杨,钟长鸣,等. 中医核心证候指标集的构建思路[J]. 中国循证医学杂志,2021,21(11):1353-1357.
|
[25] |
|
[26] |
|
[27] |
张冬,张明妍,郑文科,等. 中医药临床试验核心指标集构建及德尔菲法实施规范[J]. 中医杂志,2017,58(1):20-22. DOI:10.13288/j.11-2166/r.2017.01.006.
|
[28] |
|
[29] |
李慧敏,杨伟,章轶立,等. 中医药治疗绝经后骨质疏松症随机对照试验结局指标的现状分析[J]. 中国中药杂志,2021,46 (16):4274-4286. DOI:10.19540/j.cnki.cjcmm.20210426.501.
|
[30] |
|
[1] | NAN Ziqing, LIN li. Progress in the Diagnosis and Treatment of Urinary Retention during Pregnancy [J]. Chinese General Practice, 2023, 26(36): 4608-4612. |
[2] | ZHANG Di, LI Hongpeng, MA Jiang, NIE Qian, SUN Jianfeng, WU Zhipeng, ZHANG Hongcai, ZHAO Jue. Effect of Ocular Acupuncture and Exercise Combination Therapy on Postoperative Heart Rate Variability and Prognosis of Patients Treated with Percutaneous Coronary Intervention [J]. Chinese General Practice, 2023, 26(36): 4535-4544. |
[3] | LUO Na, RUAN Yanqin, LEI Pingguang, WAN Chonghua, WAN Keyan, SONG Ying, CHEN Ying. Analysis of the Measurement Characteristics of Inflammatory Bowel Disease Patient-reported Outcomes Measurement Scale [J]. Chinese General Practice, 2023, 26(36): 4602-4607. |
[4] | LU Yihan, WANG Jiwen, SUN Yue, FENG Runrun, HAN Yufei, SONG Zhenzhen, SUN Ying, DAI Huihua, CHEN Xing. Risk Factors and Maternal and Neonatal Outcomes of Pregnant Women with Total Labor over 24 Hours [J]. Chinese General Practice, 2023, 26(35): 4459-4463. |
[5] | XU Man, AN Zhuoling, ZHANG Yuhui, MA Zhuo. Current Situation of Potentially Inappropriate Medication in Older Cancer Patients and Strategies to Address It [J]. Chinese General Practice, 2023, 26(35): 4382-4387. |
[6] | Expert Consensus Writing Group of Integrated Traditional Chinese and Western Medicine Management for Chronic Obstructive Pulmonary Disease. Expert Consensus on Integrated Traditional Chinese and Western Medicine Management for Chronic Obstructive Pulmonary Disease (2023 Edition) [J]. Chinese General Practice, 2023, 26(35): 4359-4371. |
[7] | LIN Kai, YAO Mi, CHEN Zhang, JI Xinxin, LIN Runqi, CHEN Yongsong, Sim MOIRA. Conceptual Framework and Responding Approach of Treatment Burden of Type 2 Diabetes: a Video Recording-based Analysis [J]. Chinese General Practice, 2023, 26(34): 4302-4307. |
[8] | YAO Yuzhong, MA Xiaojun, SONG Huan, ZHONG Yu. The Management Effect of Diabetes "1358 model" on Community Diabetes Patients Based on "Precision Management Combining General Care and Specialty Care" [J]. Chinese General Practice, 2023, 26(34): 4308-4314. |
[9] | WANG Xu, WEI Xu, ZHU Liguo, FENG Tianxiao, WANG Zhipeng, SHI Bin. Research Ideas of the Efficacy Mechanism and Prospect Analysis of Traditional Chinese Manipulative Therapy on Treating Spinal Degenerative Diseases with Combination of Medicine and Industry [J]. Chinese General Practice, 2023, 26(33): 4118-4124. |
[10] | WANG Minghuan, LI Yuhong, YU Min, WANG Yougang, YU Qiaozhi, YANG Fangfang, YUAN Dehui, ZHANG Liu. Effect of Allostatic Load on Adverse Pregnancy Outcomes of Women in Late Pregnancy [J]. Chinese General Practice, 2023, 26(32): 4064-4069. |
[11] | GAO Jing, ZHOU Shangcheng, GAO Sande, ZOU Guanyang, CHEN Yingyao. Health-related Quality of Life and Its Influencing Factors in Patients with Prevention of Disease in Traditionnal Chinese Medicine based on EQ-5D-5L Scale [J]. Chinese General Practice, 2023, 26(32): 4043-4050. |
[12] | LI Qian, ZHANG Yunshu, YAN Baoping, WANG Jian, MA Yanjuan, WANG Yuan, QIN Yingjie, NA Long, REN Zhiyong, SUN Junwei, DENG Huaili, MA Hongjun, QU Xuehui, ZHOU Nan, SI Tianmei. Efficacy and Safety of Risperidone Microspheres for Injection (Ⅱ) in the Treatment of Patients with Acute Schizophrenia [J]. Chinese General Practice, 2023, 26(32): 4007-4012. |
[13] | HE Jingyi, WANG Fang, SHUI Xiaoling, LI Ling, LIANG Qian. Efficacy of Non-pharmacological Interventions to Improve Perimenopausal Insomnia Symptoms: a Network Meta-analysis [J]. Chinese General Practice, 2023, 26(31): 3963-3974. |
[14] | QU Hui, LI Huan, TANG Ruohan, DU Yuzheng, ZHAO Qi. Outcome Indicators Analysis of Randomized Controlled Trials of Acupuncture for Obstructive Sleep Apnea Hypopnea Syndrome in the Past Decade [J]. Chinese General Practice, 2023, 26(30): 3734-3739. |
[15] | WEI Mengyu, WANG Jiajia, ZHANG Yingying, LI Chunyang, LI Jiansheng. Research Status of Patient-reported Outcome Assessment Tools for Obstructive Sleep Apnea [J]. Chinese General Practice, 2023, 26(30): 3725-3733. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||